Skip to content

Study · Animal study (in vivo) · mouse · 2019

2 results

Earlier changes in mice after D-galactose treatment were improved by mitochondria derived small peptide MOTS-c.

Li Q, Lu H, Hu G, Ye Z, Zhai D, Yan Z, Wang L, Xiang A, Lu Z

Biochemical and biophysical research communications6 Apr 2019Cited by 34 (Europe PMC)

PMID30967270 (opens in a new tab)DOI10.1016/j.bbrc.2019.03.194 (opens in a new tab)PepBankPUB-30967270
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In D-galactose aged mice, MOTS‑c treatment largely alleviated lipid accumulation in liver, visceral fat and dermal skin.

    In plain wordsIn aging-model mice, MOTS‑c treatment largely reduced fat build-up in liver, belly fat and skin.

    Peptide
    MOTS-c
    Outcome
    DecreaseLipid accumulation in liver, visceral fat and dermal skin
    Study

    mousen: not reported in source

    D-galactose chronic injection model
    Comparator
    D-galactose mice
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c treatment largely alleviated the lipid accumulations, corresponding with positive changes in mitochondria dynamics, observed in liver transmission electron microscopy and in altered mRNA levels of Drp1 and mitofusins.
    2 context sentences
    Summary · context
    Tissue morphology analyses disclosed that liver, visceral fat and dermal skin, all displayed aberrant lipid depositions in the D-galactose mice.
    Summary · context
    Here, in the D-galactose chronic injection models, exogenous MOTS-c was given to determine its direct anti-aging effects.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In D-galactose aged mice, MOTS‑c treatment came with positive changes in mitochondria dynamics and altered mRNA levels of Drp1 and mitofusins.

    In plain wordsIn aging-model mice, MOTS‑c treatment came with better mitochondria shape changes and altered activity of genes Drp1 and mitofusins.

    Peptide
    MOTS-c
    Outcome
    MixedMitochondria dynamics and Drp1 and mitofusin mRNA
    Study

    mousen: not reported in source

    D-galactose chronic injection model
    Comparator
    D-galactose mice
    Outcome group
    Mitochondrial function · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c treatment largely alleviated the lipid accumulations, corresponding with positive changes in mitochondria dynamics, observed in liver transmission electron microscopy and in altered mRNA levels of Drp1 and mitofusins.
    1 context sentence
    Summary · context
    Here, in the D-galactose chronic injection models, exogenous MOTS-c was given to determine its direct anti-aging effects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.